Youle Zheng, Jin Feng, Yixin Yu, Min Ling, Xu Wang
{"title":"Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies","authors":"Youle Zheng, Jin Feng, Yixin Yu, Min Ling, Xu Wang","doi":"10.1007/s12272-024-01493-2","DOIUrl":null,"url":null,"abstract":"<div><p>Sarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in managing sarcopenia. However, it is important to consider the variable efficacy and potential side effects associated with these treatments. There are currently no drugs approved by the Food and Drug Administration for sarcopenia. The ongoing research aims to develop more effective strategies in the future. Our review of research on disease mechanisms and drug development will be a valuable contribution to future research endeavors.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Pharmacal Research","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12272-024-01493-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Sarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in managing sarcopenia. However, it is important to consider the variable efficacy and potential side effects associated with these treatments. There are currently no drugs approved by the Food and Drug Administration for sarcopenia. The ongoing research aims to develop more effective strategies in the future. Our review of research on disease mechanisms and drug development will be a valuable contribution to future research endeavors.
肌肉疏松症是一种以肌肉量减少为特征的多因素疾病。它对全球老年人的健康构成重大威胁。据报道,有药物和非药物方法可用于治疗这种疾病。某些饮食模式,如充足的能量摄入和必需氨基酸,对保持肌肉功能有积极作用。各种药物,包括肌生成抑制素抑制剂、生长激素和活化素 II 型受体抑制剂,在控制肌肉疏松症方面的效果均已得到评估。不过,必须考虑到这些治疗方法的疗效不一,而且可能会产生副作用。目前,美国食品和药物管理局尚未批准治疗肌肉疏松症的药物。正在进行的研究旨在未来开发出更有效的策略。我们对疾病机理和药物开发研究的回顾,将为未来的研究工作做出宝贵贡献。
期刊介绍:
Archives of Pharmacal Research is the official journal of the Pharmaceutical Society of Korea and has been published since 1976. Archives of Pharmacal Research is an interdisciplinary journal devoted to the publication of original scientific research papers and reviews in the fields of drug discovery, drug development, and drug actions with a view to providing fundamental and novel information on drugs and drug candidates.